ROMAN PEREZ-SOLER, MD
Osteopathic Medicine at 210 St, Bronx, NY
License number
New York 211726
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
111 EAST 210Th St, Bronx, NY 10467
404 E 76Th St APT 25A, New York, NY 10021
404 E 76Th St APT 25A, New York, NY 10021
Phone
(718) 920-4001
(718) 798-7474 (Fax)
(718) 798-7474 (Fax)
Personal information
See more information about ROMAN PEREZ-SOLER at radaris.comName
Address
Phone
East Setauket, NY
120 87Th St, New York, NY 10128
301 57Th St, New York, NY 10019
404 76Th St, Manhattan, NY 10021
530 1 St, New York, NY 10016
Organization information
See more information about ROMAN PEREZ-SOLER at bizstanding.comRoman Perez-Soler MD
111 E 210 St, Bronx, NY 10467
Industry:
Oncology, Internist
Phone:
(718) 920-4001 (Phone)
Roman Perez-Soler
Professional information
Methods For Treating Bronchial Premalignancy And Lung Cancer
US Patent:
2010005, Mar 4, 2010
Filed:
Aug 24, 2009
Appl. No.:
12/583642
Inventors:
Yiyu Zou - Bronx NY, US
Roman Perez-Soler - New York NY, US
Roman Perez-Soler - New York NY, US
International Classification:
A61K 9/12, A61K 31/706, A61P 35/00
US Classification:
424 45, 514 43
Abstract:
The present invention is directed to methods for treating bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to methods for decreasing the likelihood of occurrence of bronchial premalignancy and/or lung cancer in a subject comprising administering to the subject an aerosolized pharmaceutical composition comprising a prophylactically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to pharmaceutical compositions for treating bronchial premalignancy and/or lung cancer in a subject comprising a therapeutically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier. The present invention is also directed to pharmaceutical compositions for decreasing the likelihood of occurrence of bronchial premalignancy and/or lung cancer in a subject comprising a prophylactically effective amount of 5-azacytidine and a pharmaceutically acceptable carrier.
Chairman, Department Of Oncology At Montefiore Medical Center
Position:
Chairman, Department of Oncology at Montefiore Medical Center
Location:
Greater New York City Area
Industry:
Medical Practice
Work:
Montefiore Medical Center
-
Chairman, Department of Oncology
Dr. Roman Perez-Soler, Bronx NY - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Montefiore Medical Ctr Onclgy
111 E 210Th St SUITE 100, Bronx 10467
(718) 920-4826 (Phone)
Albert Enstn Cncr Mntfr Med Prk
1695 Eastchester Rd SUITE 2, Bronx 10461
(718) 405-8505 (Phone)
111 E 210Th St SUITE 100, Bronx 10467
(718) 920-4826 (Phone)
Albert Enstn Cncr Mntfr Med Prk
1695 Eastchester Rd SUITE 2, Bronx 10461
(718) 405-8505 (Phone)
Certifications:
Internal Medicine, 1987, Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Montefiore Medical Ctr Onclgy
111 E 210Th St SUITE 100, Bronx 10467
Albert Enstn Cncr Mntfr Med Prk
1695 Eastchester Rd SUITE 2, Bronx 10461
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Barnabas Hospital
4422 3Rd Ave, Bronx 10457
111 E 210Th St SUITE 100, Bronx 10467
Albert Enstn Cncr Mntfr Med Prk
1695 Eastchester Rd SUITE 2, Bronx 10461
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Barnabas Hospital
4422 3Rd Ave, Bronx 10457
Education:
Medical School
AUTONOMOUS UNIVERSITY OF BARCELONA / FACULTY OF MEDICINE
U Autonoma Barcelona
Univ of Tex MD Anderson Cancer Center
AUTONOMOUS UNIVERSITY OF BARCELONA / FACULTY OF MEDICINE
U Autonoma Barcelona
Univ of Tex MD Anderson Cancer Center
Methods And Compositions For The Manufacture Of Highly Potent Anthracycline-Based Antitumor Agents
US Patent:
6437105, Aug 20, 2002
Filed:
Nov 2, 1999
Appl. No.:
09/432190
Inventors:
Waldemar Priebe - Houston TX
Teresa Przewloka - Acton MA
Izabela Fokt - The Woodlands TX
Yi-He Ling - New York NY
Roman Perez-Soler - New York NY
Teresa Przewloka - Acton MA
Izabela Fokt - The Woodlands TX
Yi-He Ling - New York NY
Roman Perez-Soler - New York NY
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07H 1524
US Classification:
536 64
Abstract:
The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-based DNA alkylators.
Methods And Compositions For The Manufacture Of Halogenated Anthracyclines With Increased Antitumor Activity, Other Anthracyclines, Halogenated Sugars, And Glycosyl Donors
US Patent:
6355784, Mar 12, 2002
Filed:
Jun 10, 1999
Appl. No.:
09/330226
Inventors:
Waldemar Priebe - Houston TX 77005
Marta Krawczyk - Lexington KY 40503
Piotr Skibicki - Warsaw 04015, PL
Izabela Fokt - The Woodlands TX 77380
Krzysztof Dziewiszek - The Woodlands TX 77380
Grzegorz Grynkiewicz - 05-092 Lomianki, PL
Roman Perez-Soler - New York NY 10016
Marta Krawczyk - Lexington KY 40503
Piotr Skibicki - Warsaw 04015, PL
Izabela Fokt - The Woodlands TX 77380
Krzysztof Dziewiszek - The Woodlands TX 77380
Grzegorz Grynkiewicz - 05-092 Lomianki, PL
Roman Perez-Soler - New York NY 10016
International Classification:
C07H 1524
US Classification:
536 64, 536 41, 536 172, 536 184, 536 187, 536122
Abstract:
The present invention discloses new and novel halogenated anthracyclines linked through the saccharide portions. These congeners show high activity in vitro against several tumor cell lines. In doxorubicin (DOX) sensitive cell lines, they are at least as cytotoxic as DOX and in some cases more so. Many of these 4â²- and 6â²-fluorinated anthracyclines are more effective against multidrug-resistant tumors than was DOX, and/or have greater effectiveness than DOX against DOX sensitive cells. The compounds of this invention also have anti-amyloidogenic effects and the use of these compounds in the treatment of Alzheimers disease is contemplated.
Gene Therapy Of Tumors Using Non-Viral Delivery System
US Patent:
7157098, Jan 2, 2007
Filed:
Jan 6, 1999
Appl. No.:
09/225699
Inventors:
Roman Perez-Soler - New York NY, US
Yiyu Zou - Houston TX, US
Yiyu Zou - Houston TX, US
International Classification:
A61K 51/00, A61K 9/127, C12N 15/88
US Classification:
424450, 424 121, 435458
Abstract:
The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.
Gene Therapy Of Tumors Using Non-Viral Delivery System
US Patent:
2006016, Jul 27, 2006
Filed:
Apr 5, 2006
Appl. No.:
11/398243
Inventors:
Roman Perez-Soler - New York NY, US
Yiyu Zou - Houston TX, US
Yiyu Zou - Houston TX, US
International Classification:
A61K 48/00, A61K 9/127
US Classification:
424450000, 514044000, 977907000
Abstract:
The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.
Methods Of Treating Cancer With High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
US Patent:
2007019, Aug 16, 2007
Filed:
Nov 3, 2006
Appl. No.:
11/592714
Inventors:
Frank Pilkiewicz - Princeton NJ, US
Roman Perez-Soler - New York NY, US
Walter Perkins - Pennington NJ, US
Yiyu Zou - Bronx NY, US
Mary Neville - Jamesburg NJ, US
Jin Lee - Belle Mead NJ, US
Roman Perez-Soler - New York NY, US
Walter Perkins - Pennington NJ, US
Yiyu Zou - Bronx NY, US
Mary Neville - Jamesburg NJ, US
Jin Lee - Belle Mead NJ, US
International Classification:
A61K 33/24, A61K 31/555, A61K 31/282
US Classification:
424649000, 514184000, 514492000
Abstract:
In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-based platinum compound formulation wherein the concentration of the platinum compound of the lipid-based platinum compound formulation is greater than about 1.2 mg/ml.
Anthracycline Antibiotics And Methods Of Treating Cancer Using The Same
US Patent:
7557090, Jul 7, 2009
Filed:
Aug 1, 2006
Appl. No.:
11/496976
Inventors:
Waldemar Priebe - Houston TX, US
Izabella Fokt - The Woodlands TX, US
Teresa Prezewloka - Acton MA, US
Marta Krawczyk - Greenfield WI, US
Piotr Skibicki - Warsaw, PL
Grzegorz Grynkiewicz - Lominaki, PL
Roman Perez-Soler - New York NY, US
Izabella Fokt - The Woodlands TX, US
Teresa Prezewloka - Acton MA, US
Marta Krawczyk - Greenfield WI, US
Piotr Skibicki - Warsaw, PL
Grzegorz Grynkiewicz - Lominaki, PL
Roman Perez-Soler - New York NY, US
Assignee:
Houston Pharmaceuticals, Inc. - Houston TX
International Classification:
A61K 31/70
US Classification:
514 34
Abstract:
The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4′ of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the preparation of anthracycline antibiotics. These anthracycline analogs show high cytotoxicity in vitro against several tumor cell lines.
Methods Of Treating Cancer With Lipid-Based Platinum Compound Formulations Administered Intraperitoneally
US Patent:
2006024, Nov 2, 2006
Filed:
Nov 8, 2005
Appl. No.:
11/269163
Inventors:
Frank Pilkiewicz - Princeton NJ, US
Roman Perez-Soler - New York NY, US
Yiyu Zou - Bronx NY, US
Kristen Pilkiewicz - , US
Roman Perez-Soler - New York NY, US
Yiyu Zou - Bronx NY, US
Kristen Pilkiewicz - , US
International Classification:
A61K 33/24, A61K 31/282, A61K 9/127
US Classification:
424450000, 424649000, 514492000
Abstract:
The present invention relates to a method of treating cancer in a patient comprising administering to the patient intraperitoneally, a cancer treating effective amount of a lipid-based platinum compound formulation.